Amplification of the HER2 gene, resulting in overexpression of the receptor, is more commonly found in nonendometrioid endometrial cancers (type II endometrial cancers) and is associated with an aggressive form of the disease with significantly shortened disease-free survival and overall survival (Hetzel et al, 1992; Acharya et al, 2005). Here, ERBB2 is linked to endometrial cancer.